A carregar...
Biochronomer™ technology and the development of APF530, a sustained release formulation of granisetron
Granisetron and other 5-hydroxytryptamine type 3 (5-HT(3)) receptor antagonists are first-line agents for preventing chemotherapy-induced nausea and vomiting (CINV). Current treatment guidelines prefer the longer-acting agent, palonosetron, for CINV prevention in some chemotherapy regimens. A new gr...
Na minha lista:
| Publicado no: | J Exp Pharmacol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4863535/ https://ncbi.nlm.nih.gov/pubmed/27186139 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JEP.S68880 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|